Mereo Biopharma Group Plc ADR (NASDAQ:MREO) has a beta value of 0.65 and has seen 1.45 million shares traded in the last trading session. The company, currently valued at $336.68M, closed the last trade at $2.17 per share which meant it lost -$0.08 on the day or -3.56% during that session. The MREO stock price is -131.34% off its 52-week high price of $5.02 and 0.46% above the 52-week low of $2.16. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.21 million shares traded. The 3-month trading volume is 1.26 million shares.
The consensus among analysts is that Mereo Biopharma Group Plc ADR (MREO) is Buy stock at the moment, with a recommendation rating of 1.11. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.01.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
Sporting -3.56% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the MREO stock price touched $2.17 or saw a rise of 20.51%. Year-to-date, Mereo Biopharma Group Plc ADR shares have moved -38.00%, while the 5-day performance has seen it change -7.66%. Over the past 30 days, the shares of Mereo Biopharma Group Plc ADR (NASDAQ:MREO) have changed -6.47%. Short interest in the company has seen 6.03 million shares shorted with days to cover at 3.82.
Wall Street analysts have a consensus price target for the stock at $7.5, which means that the shares’ value could jump 71.07% from current levels. The projected low price target is $4.0 while the price target rests at a high of $8.0. In that case, then, we find that the current price level is -268.66% off the targeted high while a plunge would see the stock gain -84.33% from current levels.
Mereo Biopharma Group Plc ADR (MREO) estimates and forecasts
The company’s shares have lost -47.58% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
7 analysts offering their estimates for the company have set an average revenue estimate of 11.89M for the current quarter. 7 have an estimated revenue figure of 4.93M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 34.82% over the past 5 years. Earnings growth for 2025 is a modest 26.19% while over the next 5 years, the company’s earnings are expected to increase by 17.79%.
MREO Dividends
Mereo Biopharma Group Plc ADR is expected to release its next earnings report on 2025-Mar-25 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders
Insiders own 0.99% of the company shares, while shares held by institutions stand at 72.63% with a share float percentage of 73.36%. Investors are also buoyed by the number of investors in a company, with Mereo Biopharma Group Plc ADR having a total of 99.0 institutions that hold shares in the company. The top two institutional holders are RUBRIC CAPITAL MANAGEMENT LP with over 15.31 million shares worth more than $55.11 million. As of 2024-06-30, RUBRIC CAPITAL MANAGEMENT LP held 2.1506% of shares outstanding.
The other major institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., with the holding of over 11.79 million shares as of 2024-06-30. The firm’s total holdings are worth over $42.45 million and represent 1.6566% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund and Tema ETF Trust-Tema GLP-1, Obesity & Cardiometabolic ETF . As of Feb 28, 2025 , the former fund manager holds about 0.02% shares in the company for having 759.1 shares of worth $1.65 million while later fund manager owns 524.03 shares of worth $1.14 million as of Nov 30, 2024 , which makes it owner of about 0.01% of company’s outstanding stock.
